Table 3.

Pathomechanisms affected by miR-137 in neurodegenerative disorders ¹.

Disease 2	Model	Pathomechanism Modifying Effects	Related Factors 3	References
AD	Aβ25–35-treated SH-SY5Y and HPN cells	miR-137-3p represses KREMEN1 and has a positive effect on pathology by contributing to increased cell viability, reduced apoptosis, and increased mitochondrial membrane potential.	SNHG1, SNHG19, KREMEN1	[48,55]
	Aβ1–42-treated SH-SY5Y cells and chemically induced AD mice	miR-137-5p reduces Aβ deposition, tau phosphorylation, and apoptosis by downregulating USP30.	USP30	[44,51]
	APP/PS1 double-transgenic AD mice	Downregulation of miR-137 coincides with upregulation of its target, CACNA1C.	CACNA1C	[51]
	AD patient cortex, TgCRND8 mice	miR-137 protects against high-fat diet-related AD risk by suppressing serine palmitoyltransferase expression that leads to lowered Aβ levels.	SPTLC1	[37,60]
	propofol-treated rats and SK-N-SH cells	miR-137-3p reduces neuronal apoptosis and restores cell proliferation by suppressing the proinflammatory neurotrophic factor PTN.	PTN	[50]
	streptozotocin-treated rats	miR-137-3p ameliorates memory impairment by downregulating MAGL (monoacylglycerol lipase), an endocannabinoid-degrading enzyme.	MAGL	[49]
PD	MPP+-induced SH-SY5Y cell model	Suppression of miR-137-3p by OIP5-AS1 leads to upregulation of the mitophagy receptor NIX, which contributes to reduced ROS levels and normalization of the mitochondrial membrane potential.	OIP5-AS1, NIX	[52]
	MPP+-induced rat primary neuronal cell	miR-137-3p decreases OXR1 levels and increases oxidative damage and apoptosis.	OXR1	[53]
	α-synuclein A30P-expressing Drosophila	Several neurotransmitter receptor targets of upregulated miR-137-3p are downregulated.	D2R, GABA-B-R3, Nmdar2	[75]
HD	HEK293T cells	miR-137-3p negatively regulates HTT translation.	HTT	[54]
	murine Hdh109/109 striatal cells	miR-137 is involved in REST-dependent transcriptional dysregulation.	REST	[85]

¹ The table contains pathomechanisms that were experimentally explored/validated in the specific disorders. ² AD: Alzheimer’s disease, PD: Parkinson’s disease, and HD: Huntington’s disease. ³ ceRNA names are underlined.